Company: CYTK
Filing Date: 2025-03-31
Form Type: PRE 14A
Source: 0001140361-25-011212
Chunk: 99

Company: CYTOKINETICS INC
Filing Date: 2025-03-31
Form: PRE 14A
Chunk 99
---
 |     | $545,637 |
| Ms. Wysenski   |     |         $78,333 |     |  $239,826 |     |  $219,978 |     | $538,137 |

| (1) | Pursuant to the Equity in Lieu of Cash Retainer Option, the following non-employee directors received shares of our Common Stock in lieu of some or all their retainers pursuant to our Equity In Lieu of Cash Retainer Option program, as follows: Dr. Harrington – 784; Dr. Henderson – 1,334; Dr. Kaye – 784; Mr. Smith – 319; Dr. Wierenga – 391; and Ms. Wysenski – 391. Amounts in this column reflect an overpayment to Ms. Parshall in the amount of $5,000, Dr. Kaye in the amount of $1,250, Dr. Henderson in the amount of $1,250, Dr. Wierenga in the amount of $1,250, and Ms. Wysenski in the amount of $1,250, in each for payments of retainer fees, which will be offset against future retainer payments in 2025. |

| (2) | Automatic grants of stock options to non-employee directors were granted at the time of the 2024 annual meeting of stockholders (May 15, 2024) at an exercise price of $60.50 per share, which represents the fair market value of our Common Stock on the date of the grant. The amounts in the table reflect the grant-date fair value of stock option grants calculated in accordance with Topic 718. Assumptions used for the valuation of these grants are set forth in Note 8 of our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The amounts in this column also reflect the incremental fair value in connection with the modification described under “—Initial and Annual Equity Grants to Non-Employee Directors” above as follows: Ms. Bhanji - $0.1 million; Mr. Costa - $0.1 million; Dr. Henderson $0.2 million; Dr. Kaye - $0.1 million; Ms. Parhsall - $0.1 million; Mr. Smith - $0.1 million; Dr. Wierenga - $0.2 million; and Ms. W